Every year, millions of infants are infected by a little-known virus that is the most common cause of respiratory disease in children. Respiratory syncytial ... in infants under 12 months of ...

Respiratory syncytial virus (RSV) infections are the leading ... The most lucrative target market is children under 2 years of age presenting with respiratory symptoms and confirmed RSV infections ...

Respiratory Syncytial Virus ... spikes are in the news, the virus is actually just as worrisome in older adults. In fact, while more than 2 million children under age 5 make an RSV-related ...

A study presented at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute ... the significant, yet often under-recognized, long-term health and economic ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab ... for otherwise healthy infants under one year of age. The 3,600-subject MK-1654-004 ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in hospitalized infants under six months of age with respiratory syncytial virus.

Among the pathogens most closely monitored for their public health impact are respiratory syncytial virus (RSV), influenza viruses, pneumococcal bacteria and SARS-CoV-2. Pneumonia does not ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute ... yet often under-recognised, long-term health and economic burden ...